Gilead Sciences Stock Forecast, Price & News

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

Is Gilead Sciences a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Gilead Sciences stock.
View analyst ratings for Gilead Sciences or view top-rated stocks.

How has Gilead Sciences' stock been impacted by COVID-19?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GILD stock has decreased by 4.8% and is now trading at $70.14.
View which stocks have been most impacted by COVID-19.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Gilead Sciences.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, October, 28th. The biopharmaceutical company reported $2.65 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.72 by $0.93. The biopharmaceutical company earned $7.42 billion during the quarter, compared to the consensus estimate of $6.31 billion. Gilead Sciences had a net margin of 26.91% and a trailing twelve-month return on equity of 56.59%. The firm's revenue was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.11 EPS.
View Gilead Sciences' earnings history.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, October 28th. Stockholders of record on Wednesday, December 15th will be paid a dividend of $0.71 per share on Thursday, December 30th. This represents a $2.84 annualized dividend and a dividend yield of 4.05%. The ex-dividend date is Tuesday, December 14th.
View Gilead Sciences' dividend history.

Is Gilead Sciences a good dividend stock?

Gilead Sciences pays an annual dividend of $2.84 per share and currently has a dividend yield of 4.12%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Gilead Sciences is 48.46%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 42.14% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share guidance of $7.900-$8.100 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.180. The company issued revenue guidance of $26 billion-$26.30 billion, compared to the consensus revenue estimate of $25.12 billion.

What price target have analysts set for GILD?

15 analysts have issued 12 month target prices for Gilead Sciences' stock. Their forecasts range from $66.00 to $625.00. On average, they expect Gilead Sciences' stock price to reach $124.58 in the next twelve months. This suggests a possible upside of 77.6% from the stock's current price.
View analysts' price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:

• Daniel P. O'Day, Chairman & Chief Executive Officer
• Andrew D. Dickinson, Chief Financial Officer
• Merdad V. Parsey, Chief Medical Officer
• Flavius Martin, Executive Vice President-Research
• Brett A. Pletcher, Secretary, Chief Compliance Officer & Executive VP (LinkedIn Profile)

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Repligen (RGEN), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of GILD's competitors.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.64%), Capital Research Global Investors (9.13%), Capital World Investors (2.95%), Geode Capital Management LLC (1.78%), Morgan Stanley (1.23%) and Bank of New York Mellon Corp (1.01%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Capital Research Global Investors, Natixis, Franklin Resources Inc., Citadel Advisors LLC, Arrowstreet Capital Limited Partnership, Healthcare of Ontario Pension Plan Trust Fund, and State of Michigan Retirement System. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Johanna Mercier, and Richard James Whitley.
View insider buying and selling activity for Gilead Sciences or view top insider-selling stocks.

Which major investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Morgan Stanley, EP Wealth Advisors LLC, MFA Wealth Advisors LLC, Nordea Investment Management AB, Capital World Investors, First Horizon Advisors Inc., and Assenagon Asset Management S.A..
View insider buying and selling activity for Gilead Sciences or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $70.14.

How much money does Gilead Sciences make?

Gilead Sciences has a market capitalization of $87.98 billion and generates $24.69 billion in revenue each year. The biopharmaceutical company earns $123 million in net income (profit) each year or $5.86 on an earnings per share basis.

How many employees does Gilead Sciences have?

Gilead Sciences employs 13,600 workers across the globe.

Does Gilead Sciences have any subsidiaries?

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, Bristol-Myers Squibb and Gilead Sciences Limited, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland UC, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Tri-Supply Limited, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..

When was Gilead Sciences founded?

Gilead Sciences was founded in 1987.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

Where are Gilead Sciences' headquarters?

Gilead Sciences is headquartered at 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at [email protected], or via fax at 650-578-9264.